Skip to main content
. Author manuscript; available in PMC: 2010 Oct 18.
Published in final edited form as: AIDS. 2009 Sep 24;23(15):1955–1964. doi: 10.1097/QAD.0b013e32832ff1ff

Table 2.

CD27/CD45RA expression in natural viral suppressors, HIV-P and African-American HIV-negative patients ex vivo (day 0) and after 14-day expansion with isopentenyl pyrophosphate.

CD27+/CD45RA+ (Mean % ±SD) CD27+/CD45RA– (Mean % ± SD) CD27–/CD45RA+ (Mean % ± SD) CD27–/CD45RA– (Mean % ± SD)
Day 0
    NVS 6.1 ± 5.0 70.6 ± 16.5 3.73 ± 5.2 19.6 ± 14.2
    AA HIV– 8.4 ± 7.0 65.7 ± 14.2 5.1 ± 5.0% 20.8 ± 12.9
    HIV-P 28.8 ± 13.6 28.5 ± 18.8 37.1 ± 21.7 5.7 ± 5.9
IPP
    NVS 0.8 ± 0.9 25.6 ± 17.4 2.0 ± 2.4 72.0 ± 17.7
    AA HIV– 8.9 ± 7.2 65.8 ± 13.9 20.1 ± 13.1 5.3 ± 5.0
    HIV-P 15.0 ± 14.8 17.2 ± 9.8 20.0 ± 19.4 47.4 ± 25.2

AA, African–American; IPP, isopentenyl pyrophosphate; NVS, natural viral suppressor.